LKFT — Lakefront Biotherapeutics N.V. stock price, charts and financials

QT53Lakefront Biotherapeutics N.V.

Lakefront Biotherapeutics N.V. (NASDAQ: LKFT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
28.55
-0.36-1.25%
OverviewShort InterestFilings
LKFTQT53Lakefront Biotherapeutics N.V.·NASDAQ
28.55-1.25%
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
RAPP-3.58%$40.45GHRS-1.60%$28.26ZYME-3.31%$26.57AGIO-1.61%$33.07ZBIO-1.47%$31.50GPCR-0.28%$35.00ADMA+1.79%$9.11KOD-0.43%$32.71
Snapshot
Index-P/E2.71EPS (ttm)10.52Insider Own-Shs Outstand65.90MPerf Week6.49%
Market Cap1.88BForward P/E-EPS next Y-3.45Insider Trans-Shs Float49.19MPerf Month-2.76%
Enterprise Value1.62BPEG-EPS next Q-0.94Inst Own-Short Float6.70%Perf Quarter0.88%
Income694.00MP/S1.63EPS this Y-130.51%Inst Trans-Short Ratio15.83Perf Half Y-12.23%
Sales1.15BP/B0.51EPS next Y-7.47%ROA17.81%Short Interest3.30MPerf YTD-12.69%
Book/sh56.35P/C0.74EPS next 5Y-ROE19.58%52W High37.78 -24.43%Perf Year-11.50%
Cash/sh38.77P/FCF-EPS past 3/5Y-ROIC18.59%52W Low25.68 11.18%Perf 3Y-20.91%
Dividend Est.-EV/EBITDA2.57Sales past 3/5Y70.32% -Gross Margin94.88%Volatility3.11% 2.26%Perf 5Y-50.89%
Dividend TTM-EV/Sales1.41EPS Y/Y TTM768.19%Oper. Margin61.57%ATR (14)0.77Perf 10Y-49.14%
Dividend Ex-Date-Quick Ratio32.82Sales Y/Y TTM287.25%Profit Margin60.23%RSI (14)53.24Recom3.00
Dividend Gr. 3/5Y-Current Ratio32.82EPS Q/Q101.87%SMA200.76%Beta0.24Target Price26.00
Payout0.00%Debt/Eq0.00Sales Q/Q-81.08%SMA501.11%Rel Volume2.00Prev Close28.91
Employees452LT Debt/Eq0.00EarningsNov 12SMA200-5.59%Avg Volume229.36KPrice28.55
IPO DateMay 05, 2005Option/ShortYes / YesEPS/Sales Surpr.112.62% 13.66%Net Debt/EBITDA-0.24Volume459,127Change-1.25%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-11-26ReiteratedMorgan StanleyEqual Weight$30 → $26
Jul-10-26ResumedMorgan StanleyEqual Weight$30
Latest News· Times ET
Sep-15-26
Sep-15-2610:01PM
Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha
12:01PM
Acquisition of Own Sharesglobenewswire.com
04:01AM
Lakefront Biotherapeutics: A Cash Discount With A More Credible Path To Valueseekingalpha.com
Sep-08-26
Sep-08-2612:02PM
Acquisition of Own Sharesglobenewswire.com
12:01PM
Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conferenceglobenewswire.com
Sep-01-26
Sep-01-2612:01PM
Acquisition of Own Sharesglobenewswire.com
Aug-25-26
Aug-25-2612:01PM
Acquisition of Own Sharesglobenewswire.com
Aug-24-26
Aug-24-2612:02PM
Bank Of America Raises Lakefront Biotherapeutics Stake Above To 10.11%Benzinga
12:01PM
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigusglobenewswire.com
12:01PM
Lakefront Receives Transparency Notification from Bank of Americaglobenewswire.com
Aug-18-26
Aug-18-2612:01PM
Acquisition of Own Sharesglobenewswire.com
Aug-12-26
Aug-12-2612:01PM
Acquisition of Own Sharesglobenewswire.com
Aug-11-26
Aug-11-2607:57AM
Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26Benzinga
Aug-10-26
Aug-10-2612:27PM
Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M EstimateBenzinga
Jul-28-26
Jul-28-2612:01PM
Acquisition of Own Sharesglobenewswire.com
Company

Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
Total Revenue1,1541,255298———
Cost of Goods Sold Incl. D&A603438———
Gross Profit1,0951,221261———
Selling, General and Administrative Excl. Other126126105———
Research and Development277518363———
Other Operating Expense-1812-4———
Operating Income709566-204———
Interest Expense031———
Unusual Expense
——————
Non-Operating Income (Expense)-38-224201———
Net Income Before Taxes671339-3———
Income Taxes-19-21-2———
Consolidated Net Income69436280———
Net Income From Continuing Operations691360-1———
Net Income69436280———
EPS (Recurring)10.525.491.21———
EPS (Basic, Before Extraordinaries)10.525.491.21———
EPS (Diluted)10.525.491.21———
EBITDA63140547———
Other After Tax Adjustments
——————
Stock Option Compensation Expense
——————
Price To Earnings Ratio2.715.9522.69———
Price To Sales Ratio1.831.726.09———
Gross Margin94.8997.2987.58———
Operating Margin61.4445.10-68.46———
Net Margin60.1428.8426.85———
Shares Outstanding746666———
Market Capitalization2,1132,1581,815———
Operating Lease Expense
——————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.